The COVID-19 Textbook

261

CHAPTER 8 • Antibodies in COVID-19

61. Benhnia MR, McCausland MM, Laudenslager J, et al . Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol . 2009;83:12355-12367. 62. Li F, Freed DC, Tang A, et al . Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination. NPJ Vaccines . 2017;2:36. 63. Nascimento EJ, Silva AM, Cordeiro MT, et al . Alternative complement pathway deregulation is correlated with dengue severity. PLoS One . 2009;4:e6782. 64. Churdboonchart V, Futrakul P, Bhamarapravati N. Crossed immunoelectrophoresis for the detection of split products of the third complement in dengue hemorrhagic fever. I. Observations in patients’ plasma. Am J Trop Med Hyg . 1983;32:569-576. 65. Füst G, Tóth FD, Kiss J, Ujhelyi E, Nagy I, Bánhegyi D . Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS . 1994;8:603-610. 66. Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D . Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis . 1990;162:1227-1232. 67. Mak TW, Saunders ME. Complement. In The Immune Response . Elsevier; 2006:553-581. doi:10.1016/B978-012088451-3.50021-1 68. West EE, Kolev M, Kemper C. Complement and the regulation of T cell responses. Annu Rev Immunol . 2018;36:309-338. 69. Smith KG, Clatworthy MR. Fc γ RIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol . 2010;10:328-343. 70. Verbeek JS, Hirose S, Nishimura H. The complex association of Fc γ RIIb with autoimmune susceptibility. Front Immunol . 2019;10:2061. 71. Kwan WH, van der Touw W, Heeger PS. Complement regulation of T cell immunity. Immunol Res . 2012;54:247-253. 72. Arvin AM, Fink K, Schmid MA, et al . A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature . 2020;584:353-363. 73. Janoff EN, Wahl SM, Thomas K, Smith PD. Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. J Infect Dis . 1995;172:855-858. 74. Kozlowski PA, Black KP, Shen L, Jackson S. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol. 1995;154:6163-6173. 75. Hawkes RA, Lafferty KJ. The enhancement of virus infectivity by antibody. Virology . 1967;33:250-261. 76. Halstead SB, O’Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med . 1977;146:201-217. 77. Halstead SB, O’Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med . 1977;146:218-229. 78. Halstead SB, O’rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature . 1977;265:739-741. 79. Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci . 1964;42:465-482. 80. Ayala-Nunez NV, Hoornweg TE, van de Pol DP, et al . How antibodies alter the cell entry pathway of dengue virus particles in macrophages. Sci Rep . 2016;6:28768. 81. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A . 2007;104:9422-9427. 82. Beltramello M, Williams KL, Simmons CP, et al . The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe . 2010;8:271-283. 83. Dejnirattisai W, Supasa P, Wongwiwat W, et al . Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol . 2016;17:1102-1108. 84. Liu L, Wei Q, Lin Q, et al . Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight . 2019;4:e123158. 85. Wang Q, Zhang L, Kuwahara K, et al . Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis . 2016;2:361-376. 86. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol . 2003;13:387-398. 87. Post N, Eddy D, Huntley C, et al . Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One . 2020;15:e0244126. 88. Piccoli L, Park YJ, Tortorici MA, et al . Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell . 2020;183:1024-1042.e21. 89. Zhou P, Yang XL, Wang XG, et al . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature . 2020;579:270-273. 90. Huang AT, Garcia-Carreras B, Hitchings MDT, et al . A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun . 2020;11:4704. 91. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med . 2007;357:1162-1163. 92. Wang Y, Zhang L, Sang L, et al . Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest . 2020;130:5235-5244. 93. Carsetti R, Zaffina S, Piano Mortari E, et al . Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol . 2020;11:610300. 94. Guthmiller JJ, Stovicek O, Wang J, et al . SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. mBio . 2021;12:e02940-20. 95. Park JH, Cha MJ, Choi H, et al . Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19. J Microbiol Immunol Infect . 2022;55:1094-1100. 96. Luo H, Jia T, Chen J, et al . The characterization of disease severity associated IgG subclasses response in COVID-19 patients. Front Immunol . 2021;12:632814. 97. Zohar T, Loos C, Fischinger S, et al . Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell . 2020;183:1508-1519.e12. 98. Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol . 2020;20:392-394. 99. Chakraborty S, Gonzalez J, Edwards K, et al . Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol . 2021;22:67-73. 100. Larsen MD, de Graaf EL, Sonneveld ME, et al . A fucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science . 2021;371:eabc8378. 101. McCallum M, De Marco A, Lempp FA, et al . N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell . 2021;184:2332-2347.e16. 102. Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol . 2020;50:101422. 103. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA . 2021;326:1533-1535. 104. Addetia A, Crawford KHD, Dingens A, et al . Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol . 2020;58:e02107-20. 105. Supasa P, Zhou D, Dejnirattisai W, et al . Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell . 2021;184:2201-2211.e7. 106. Liu C, Ginn HM, Dejnirattisai W, et al . Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell . 2021;184:4220 4236.e13. 107. Dejnirattisai W, Huo J, Zhou D, et al . SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell . 2022;185:467-484.e15.

Copyright © 2023 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.